The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
Open accessPublished version of a preprint
Abstract
Although the number of proteins effectively targeted for posttranslational degradation by PROTAC has grown steadily, the number of E3 ligases successfully exploited to accomplish this has been limited to the few for which small-molecule ligands have been discovered. Although the E3 ligase MDM2 is bound by the nutlin class of small-molecule ligands, there are few nutlin-based PROTAC. Because a nutlin-based PROTAC should both knockdown its target protein and upregulate the tumor suppressor p53, we examined the ability of such a PROTAC to decrease cancer cell viability. A nutlin-based, BRD4-degrading PROTAC, A1874, was able to degrade its target protein by 98% with nanomolar potency. Given the complementary ability of A1874 to stabilize p53, we discovered that the nutlin-based PROTAC was more effective in inhibiting proliferation of many cancer cell lines with wild-type p53 than was a corresponding VHL-utilizing PROTAC with similar potency and efficacy to degrade BRD4. This is the first report of a PROTAC in which the E3 ligase ligand and targeting warhead combine to exert a synergistic antiproliferative effect. Our study highlights the untapped potential that may be unlocked by expanding the repertoire of E3 ligases that can be recruited by PROTAC. Significance: These findings present the first BRD4-targeting MDM2-based PROTAC that possesses potent, distinct, and synergistic biological activities associated with both ends of this heterobifunctional molecule.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This PROTAC, A1874, degraded BRD4 almost completely in HCT116 cells at 100 nM within 24 h.”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [68]
In the citing paper
“It was recently shown that a MDM2-based PROTAC could synergistically combine a catalytic mechanism of action, via degradation of a neo-substrate, and an occupancy-based effect, via competition with, and stabilization of, the endogenous substrate p53 (ref. 60 ).”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Self-citationIdentification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Ubiquitin ligases: structure, function, and regulation
Zheng, N., & Shabek, N. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014922 · Cited by 1,499
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Self-citationStructural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Self-citationAnalysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
Cited by
Sorted by citations
Items 101–200 of 358
A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
Skalniak, Ł., Surmiak, E., & Holak, T. A. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1582645 · Cited by 45
Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities
Song, R., Qiao, W., He, J., Huang, J., Luo, Y., & Yang, T. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01640 · Cited by 45
Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway
Kim, H., Park, J., & Kim, J. (2022) · Biomedicines · doi:10.3390/biomedicines10092100 · Cited by 45
Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery
Xi, J., Zhang, R., Chen, K., Yao, L., Li, M., Jiang, R., Li, X., & Fan, L. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105848 · Cited by 47
PROTACs: New method to degrade transcription regulating proteins
Hu, B.-C., Zhou, Y., Sun, D., Yang, Y., Liu, Y., Li, X., Li, H., & Chen, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112698 · Cited by 43
The Ubiquitin Proteasome System in Genome Stability and Cancer
Morgan, J. J., & Crawford, L. (2021) · Cancers · doi:10.3390/cancers13092235 · Cited by 40
Degraders in epigenetic therapy: PROTACs and beyond
Dai, X., Ji, S., Fu, M., Liu, G.-Z., Liu, H., Wang, S., Shen, L., Wang, N., Herdewijn, P. A., Zheng, Y., et al. (2024) · Theranostics · doi:10.7150/thno.92526 · Cited by 46
Targeting MYCN in Molecularly Defined Malignant Brain Tumors
Borgenvik, A., Čančer, M., Hutter, S., & Swartling, F. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.626751 · Cited by 43
Setia, N., Almuqdadi, H. T. A., & Abid, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116041 · Cited by 43
Rana, S., Mallareddy, J. R., Singh, S., Boghean, L., & Natarajan, A. (2021) · Cancers · doi:10.3390/cancers13215506 · Cited by 43
Recent advances in targeted protein degraders as potential therapeutic agents
Yang, N., Kong, B., Zhu, Z., Huang, F., Zhang, L., Lu, T., Chen, Y., Zhang, Y., & Jiang, Y. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10606-w · Cited by 44
Repurposing AS1411 for constructing ANM-PROTACs
Fu, X., Li, J., Chen, X., Chen, H., Wang, Z., Qiu, F., Xie, D., Huang, J., Yue, S., Cao, C., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.03.011 · Cited by 41
Targeted Protein Degradation through Recruitment of the CUL4 Complex Adaptor Protein DDB1
Meyers, M., Cismoski, S., Panidapu, A., Chie-Leon, B., & Nomura, D. K. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00487 · Cited by 46
Targeting the Undruggable: Recent Progress in PROTAC-Induced Transcription Factor Degradation
Jung, H., & Lee, Y. (2025) · Cancers · doi:10.3390/cancers17111871 · Cited by 41
Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
Fan, G., Chen, S., Zhang, Q., Yu, N., Shen, Z., Liu, Z., Guo, W., Tang, Z., Yang, J., & Liu, M. (2025) · MedComm · doi:10.1002/mco2.70401 · Cited by 49
Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 38
Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Zhang, S., Chen, Y., Tian, C., He, Y., Tian, Z., Wan, Y., & Liu, T. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200610174453 · Cited by 37
PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
Liu, X., Wang, A., Shi, Y., Dai, M., Liu, M., & Cai, H. (2023) · Molecules · doi:10.3390/molecules28031217 · Cited by 38
ByeTAC: Bypassing E-Ligase-Targeting Chimeras for Direct Proteasome Degradation
Loy, C. A., Ali, E. M. H., Seabrook, L. J., Harris, T. J., Kragness, K. A., Albrecht, L. V., & Trader, D. J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00485 · Cited by 42
Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
Liu, J., Peng, Y., & Wei, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.678077 · Cited by 39
Designing HDAC-PROTACs: Lessons Learned So Far
Fischer, F., Avelar, L. A. A., Murray, L., & Kurz, T. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0206 · Cited by 38
Targeted protein degraders march towards the clinic for neurodegenerative diseases
Kumar, D., & Hassan, M. I. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101616 · Cited by 38
Applications of protein ubiquitylation and deubiquitylation in drug discovery
Chen, Y., Xue, H., & Jin, J. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107264 · Cited by 42
Dying to Survive—The p53 Paradox
Lees, A., Sessler, T., & McDade, S. S. (2021) · Cancers · doi:10.3390/cancers13133257 · Cited by 38
A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer
Lier, S., Sellmer, A., Orben, F., Heinzlmeir, S., Krauß, L., Schneeweis, C., Hassan, Z., Schneider, C., Patricia Gloria Schäfer, A., Pongratz, H., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105505 · Cited by 37
PROTAC: targeted drug strategy. Principles and limitations
Koroleva, O. A., Dutikova, Y. V., Trubnikov, A. V., Zenov, F. A., Manasova, E. V., Shtil, A. A., & Kurkin, A. V. (2022) · Russian Chemical Bulletin · doi:10.1007/s11172-022-3659-z · Cited by 38
Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation
Hong, S. H., Divakaran, A., Osa, A., Huang, O. W., Wertz, I. E., & Nomura, D. K. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00642 · Cited by 38
Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
Kim, K., Lee, D.-H., Park, S., Jo, S.-H., Ku, B., Park, S. G., Park, B. C., Jeon, Y. U., Ahn, S., Kang, C. H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56177-5 · Cited by 37
A PROTAC targets splicing factor 3B1
Gama-Brambila, R. A., Chen, J., Zhou, J., Tascher, G., Münch, C., & Cheng, X. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.018 · Cited by 37
Wang, J., Rong, Q., Ye, L., Fang, B., Zhao, Y., Sun, Y., Zhou, H., Wang, D., He, J., Cui, Z., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00051 · Cited by 35
Scaffold hopping enables direct access to more potent PROTACs with in vivo activity
Burslem, G. M., Bondeson, D. P., & Crews, C. M. (2020) · Chemical Communications · doi:10.1039/d0cc02201b · Cited by 35
Self-citationSelectively targeting individual bromodomain: Drug discovery and molecular mechanisms
Wang, Q., Shao, X., Leung, E. L., Chen, Y., & Yao, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105804 · Cited by 34
A comprehensive review of BET-targeting PROTACs for cancer therapy
Zhou, X., Zhao, F., Xu, Y.-T., Guan, Y., Yu, T., Zhang, Y., Duan, Y., & Zhao, Y. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117033 · Cited by 36
Chemically induced degradation of epigenetic targets
Kabir, M., Yu, X., Kanıskan, H. Ü., & Jin, J. J. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00100h · Cited by 36
What influences the activity of Degrader−Antibody conjugates (DACs)
Guo, Y., Li, X., Xie, Y., & Wang, D. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116216 · Cited by 38
Identification and characterization of cancer vulnerabilities via targeted protein degradation
Mayor-Ruiz, C., & Winter, G. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.12.003 · Cited by 33
An updated patent review of BRD4 degraders
Ma, Z., Zhang, C., Bolinger, A. A., & Zhou, J. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2400166 · Cited by 35
Precision-engineered PROTACs minimize off-tissue effects in cancer therapy
Shi, J., Wang, L., Zeng, X., Xie, C., Meng, Z., Campbell, A., Wang, L., Fan, H., & Sun, H. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1505255 · Cited by 35
Zou, Q., Liu, M., Liu, K., Zhang, Y., North, B. J., & Wang, B. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00777-x · Cited by 31
From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation
Wang, S., He, F., Tian, C., & Sun, A. (2024) · Pharmaceuticals · doi:10.3390/ph17010100 · Cited by 34
Methylarginine targeting chimeras for lysosomal degradation of intracellular proteins
Seabrook, L. J., Franco, C. N., Loy, C. A., Osman, J. M., Fredlender, C., Zimak, J., Campos, M., Nguyen, S. T., Watson, R. L., Levine, S. R., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01741-y · Cited by 34
Targeting epigenetic reader domains by chemical biology
Cipriano, A., Sbardella, G., & Ciulli, A. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.05.006 · Cited by 30
Expanding the ligand spaces for E3 ligases for the design of protein degraders
Saleem, R. S. Z., Schwalm, M. P., & Knapp, S. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117718 · Cited by 31
Temaj, G., Chichiarelli, S., Telkoparan‐Akillilar, P., Saha, S., Nuhii, N., Hadžiselimović, R., & Saso, L. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116332 · Cited by 34
p53 in colorectal cancer: from a master player to a privileged therapy target
Yan, S., Zhan, F., He, Y., Zhu, Y., & Ma, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06566-4 · Cited by 33
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
Chernobrovkin, A. L., Cázares-Körner, C., Friman, T., Caballero, I. M., Amadio, D., & Molina, D. M. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220984372 · Cited by 28
Chemical Biology Tools for Protein Lysine Acylation
Xie, Y., Du, S., Liu, Z., Liu, M., Xu, Z., Wang, X., Kee, J. X., Yi, F., Sun, H., & Yao, S. Q. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202200303 · Cited by 29
Liang, X., Ren, H., Han, F., Liang, R., Zhao, J., & Liu, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21992 · Cited by 31
Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment
Fan, L., Tong, W., Wei, A., & Mu, X. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133680 · Cited by 30
Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions
Vikal, A., Maurya, R., Patel, B. B., Sharma, R. K., Patel, P., Patil, U. K., & Kurmi, B. D. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01754-z · Cited by 29
The application of ubiquitin ligases in the PROTAC drug design
Chen, Y., & Jin, J. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa053 · Cited by 29
Recent advances in induced proximity modalities
Ng, C. S. C., & Banik, S. M. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.102107 · Cited by 27
Wang, H., Li, C., Liu, X., & Ma, M. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116707 · Cited by 28
Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
Yuan, M., Chu, Y., & Duan, Y. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.691093 · Cited by 27
Yang, J., Ruan, Y., Wang, D., Fan, J., Luo, N., Chen, H., Li, X., Chen, W., & Wang, X. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00936-x · Cited by 28
Molecular glues of the regulatory ChREBP/14-3-3 complex protect beta cells from glucolipotoxicity
Katz, L. S., Visser, E. J., Plitzko, K., Pennings, M. A. M., Cossar, P. J., Tse, I., Kaiser, M., Brunsveld, L., Ottmann, C., & Scott, D. K. (2025) · Nature Communications · doi:10.1038/s41467-025-57241-7 · Cited by 28
PROTACs in gastrointestinal cancers
Chen, Y., Yang, Q., Xu, J., Tang, L., Zhang, Y., Du, F., Zhao, Y., Wu, X., Li, M., Shen, J., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.10.012 · Cited by 29
Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress
Chen, J., Feng, D., Zhu, R., Li, H., & Chen, L. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103781 · Cited by 29
Recent advances in developing targeted protein degraders
Cheng, B., Li, H., Peng, X., Chen, J., Shao, C., & Kong, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117212 · Cited by 28
Bayesian optimization for ternary complex prediction (BOTCP)
Rao, A., Tunjic, T. M., Brunsteiner, M., Müller, M., Fooladi, H., Gasbarri, C., & Weber, N. (2023) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2023.100072 · Cited by 25
Li, Y., Li, G., Zuo, C., Wang, X., Han, F., Jia, Y., Shang, H., & Tian, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116367 · Cited by 27
Recent advances in dual PROTACs degrader strategies for disease treatment
Liu, J., Liu, Y., Tang, J., Gong, Q., Yan, G., Fan, H., Zhang, X., & Pu, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116901 · Cited by 25
Rational design of the linkers in targeting chimeras
Duan, Y., Cai, M. Y., Xu, J., & Hu, Q. (2025) · Chemical Science · doi:10.1039/d5sc04859a · Cited by 25
Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
Sachkova, A. A., Andreeva, D. V., Tikhomirov, A. S., Scherbakov, A. M., Salnikova, D. I., Sorokin, D. V., Bogdanov, F. B., Rysina, Y. D., Shchekotikhin, A. E., Shchegravina, E. S., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122829 · Cited by 24
Structure driven compound optimization in targeted protein degradation
Leissing, T. M., Luh, L. M., & Cromm, P. M. (2020) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2020.11.005 · Cited by 22
Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
Severini, L. L., Bufalieri, F., Infante, P., & Marcotullio, L. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.854352 · Cited by 23
Ohoka, N., Suzuki, M., Uchida, T., Tsuji, G., Tsukumo, Y., Yoshida, M., Inoué, T., Demizu, Y., Ohki, H., & Naito, M. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00402 · Cited by 23
Advancing Design Strategy of PROTACs for Cancer Therapy
Luo, H., Tian, Y., Abdullah, R., Zhang, B., Ma, Y., & Zhang, G. (2025) · MedComm · doi:10.1002/mco2.70258 · Cited by 24
Discovery of Coumarin-Based MEK1/2 PROTAC Effective in Human Cancer Cells
Wang, C., Wang, H., Zheng, C., Li, B., Liu, Z., Zhang, L., Yuan, L., & Xu, P. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00446 · Cited by 23
Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy
Groppe, J. C. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1660641 · Cited by 22
Lucas, S. C. C., Ahmed, A., Ashraf, S. N., Argyrou, A., Bauer, M. R., Donatis, G. M. D., Demanze, S., Eisele, F., Fusani, L., Hock, A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02136 · Cited by 23
Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Barghout, S. H. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200410082652 · Cited by 21
Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs)
Tomaselli, D., Mautone, N., Mai, A., & Rotili, D. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112750 · Cited by 21
Kong, Y., Lan, T., Wang, L., Chen, G., Lv, W., Zhang, H., Zhou, C., Sun, X., Liu, W., Haihui, H., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03121-1 · Cited by 25
Computational strategies for PROTAC drug discovery
Wu, J., Wang, W., & Leung, C. (2023) · Acta Materia Medica · doi:10.15212/amm-2022-0041 · Cited by 22
Lv, M., Hu, W., Zhang, S., He, L., Hu, C., & Yang, S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215716 · Cited by 19
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20
Gross, P. H., Sheets, K. J., Warren, N. A., Ghosh, S., Varghese, R. E., Wass, K. E., & Kadimisetty, K. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.08.048 · Cited by 19
Wang, W., Li, Y., Tang, L., Shi, Y., Li, W., Zou, L., Zhang, L., Cheng, Y., Zheng, Y., Zhu, F., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216849 · Cited by 19
Ubiquitin–proteasome system-targeted therapy for uveal melanoma: what is the evidence?
Zhao, C., Zeng, C., Wang, K., He, Q., Yang, B., Zhou, F., & Zhu, H. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0441-3 · Cited by 18
BRD4 promotes gouty arthritis through MDM2-mediated PPARγ degradation and pyroptosis
Xu, X., & Qiu, H. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00831-w · Cited by 17
Liu, Y., Zhang, X., Chen, X., & Zhang, F. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2025.123621 · Cited by 20
Upregulation of p53 through induction of MDM2 degradation: Anthraquinone analogs
Draganov, A. B., Yang, X., Anifowose, A., Cruz, L. K. D. L., Dai, C., Ni, N., Chen, W., Santos, Z. A. D. L., Gu, L., Zhou, M., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.07.019 · Cited by 17
Kaji, T., Koga, H., Kuroha, M., Akimoto, T., & Hayata, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-59966-5 · Cited by 16
Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
Li, Q., Zhou, L., Qin, S., Huang, Z., Li, B., Li, B., Yang, M., Nice, E. C., Zhu, H., & Huang, C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115447 · Cited by 17
Deng, Z., Catlett, J. L., Lee, Y., Wu, Q. D., Xu, Z., Xie, L., Chen, X., Xiong, Y., Kanıskan, H. Ü., & Jin, J. J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00295 · Cited by 18
Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios
Verano, A. L., You, I., Donovan, K. A., Mageed, N., Yue, H., Nowak, R. P., Fischer, E. S., Wang, E. S., & Gray, N. S. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00439 · Cited by 16
Functional roles of E3 ubiquitin ligases in prostate cancer
Zhao, Y., Li, J., Chen, J., Ye, M., & Jin, X. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02229-9 · Cited by 15
PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance
Giardina, S. F., Valdambrini, E., Warren, J. D., & Barany, F. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210203110857 · Cited by 14
Design, synthesis, and biological evaluation of Wee1 kinase degraders
Zhu, S., Liu, J., Xiao, D., Wang, P., Ma, J., Hu, X., Fu, J., Zhou, Y., Li, J. X., & Lu, W. P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114786 · Cited by 15
Protein-Targeted Degradation Agents Based on Natural Products
Li, Y., Jia, Y., Wang, X., Shang, H., & Tian, Y. P. (2022) · Pharmaceuticals · doi:10.3390/ph16010046 · Cited by 14
Uno, S., Harkiss, A. H., Chowdhury, R., Caldwell, S. T., Prime, T. A., James, A. M., Gallagher, B., Prudent, J., Hartley, R. C., & Murphy, M. P. (2023) · ChemBioChem · doi:10.1002/cbic.202200774 · Cited by 13
Yan, Z., Lyu, X., Lin, D., Wu, G., Gong, Y., Ren, X., Xiao, J., Lou, J., Huang, H., Chen, Y., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115381 · Cited by 14
Xu, M., Xia, Z.-Y., Sun, J., Liu, C., An, Y., Xu, J., Zhang, S.-H., Zhong, X., Zeng, N., Ma, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1395047 · Cited by 14
Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules
Delport, A., & Hewer, R. (2019) · Molecules · doi:10.3390/molecules24183272 · Cited by 14
In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs)
Tomoshige, S., & Ishikawa, M. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116221 · Cited by 17
MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53
Chang, M., Gao, F., Chen, J., Gnawali, G. R., & Wang, W. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0022 · Cited by 18
Chimera induced protein degradation: PROTACs and beyond
Yin, L., & Hu, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112494 · Cited by 14
BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells
Zhou, X. Y., Sun, T., Meng, Y., Luo, J., Chen, J., Xia, B., Zhang, Z., Cheng, Z., & Wang, X. (2021) · Oncology Reports · doi:10.3892/or.2021.8021 · Cited by 13
Metadata
- Authors
- Hines, J., Lartigue, S., Dong, H., Qian, Y., & Crews, C. M.
- Affiliations
- Yale University (US)
- Arvinas (United States) (US)
- Corresponding author
- Crews, Craig M.
- Venue
- Cancer Research
- Published
- 2019-01-01
- Volume
- 79
- Issue
- 1
- Pages
- 251-262
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC6318015
- OpenAlex
- W2898621430
- Cited by
- 348
- References
- 56
- Citations by year
- 2026: 30 · 2025: 49 · 2024: 52 · 2023: 41 · 2022: 60 · 2021: 45 · 2020: 45 · 2019: 25
- FWCI
- 10.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NCI (R50 CA211252)
- NIH (R35 CA197589)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- PROTACs, MDM2, BRD4 degradation, p53 stabilization, nutlin, E3 ubiquitin ligase, VHL, antiproliferative activity, drug synergy, heterobifunctional molecules, tumor cell proliferation
- MeSH terms
- Bromodomain Containing Proteins, Drug Synergism, Fibrinolytic Agents, Humans, Neoplasms, Nuclear Proteins, Peptides, Transcription Factors, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Cell Cycle Proteins, Cell Proliferation, Proto-Oncogene Proteins c-mdm2, Protein Stability, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
